Betahistine dihydrochloride - CAS 5579-84-0
Catalog: |
BB029179 |
Product Name: |
Betahistine dihydrochloride |
CAS: |
5579-84-0 |
Synonyms: |
N-methyl-2-pyridin-2-ylethanamine;dihydrochloride |
Related CAS: | 5638-76-6 54856-23-4 (mesylate)
|
IUPAC Name: | N-methyl-2-pyridin-2-ylethanamine;dihydrochloride |
Description: | Betahistine is a histamine H3 receptors inhibitor with IC50 of 1.9 μM. |
Molecular Weight: | 209.12 |
Molecular Formula: | C8H12N2 · 2HCl |
Canonical SMILES: | CNCCC1=CC=CC=N1.Cl.Cl |
InChI: | InChI=1S/C8H12N2.2ClH/c1-9-7-5-8-4-2-3-6-10-8;;/h2-4,6,9H,5,7H2,1H3;2*1H |
InChI Key: | XVDFMHARQUBJRE-UHFFFAOYSA-N |
Boiling Point: | 210.9 °C at 760 mmHg |
Purity: | > 98 % |
Density: | 0.967 g/cm3 |
LogP: | 2.83840 |
GHS Hazard Statement: | H315 (98.04%): Causes skin irritation [Warning Skin corrosion/irritation] |
Precautionary Statement: | P261, P264, P271, P273, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
US-10973908-B1 | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine | 20200514 |
US-10940088-B1 | Method of preparing low dose pharmaceutical formulations | 20200109 |
WO-2021101836-A1 | Antimalarial agents | 20191119 |
WO-2021085999-A1 | L-methionine producing microorganism to which protein encoded by foreign metz gene is introduced and method for producing l-methionine using same | 20191028 |
WO-2021072289-A1 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | 20191010 |
PMID | Publication Date | Title | Journal |
22624822 | 20121001 | Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability | British journal of pharmacology |
21770719 | 20120901 | Development of novel sustained release matrix pellets of betahistine dihydrochloride: effect of lipophilic surfactants and co-surfactants | Pharmaceutical development and technology |
22695490 | 20120901 | Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model | Journal of psychopharmacology (Oxford, England) |
22487127 | 20120601 | Involvement of histamine receptors in SAPK/JNK phosphorylation | International immunopharmacology |
22506537 | 20120601 | Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study | Clinical drug investigation |
Complexity: | 83.3 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 3 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 208.0534038 |
Formal Charge: | 0 |
Heavy Atom Count: | 12 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 3 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 208.0534038 |
Rotatable Bond Count: | 3 |
Topological Polar Surface Area: | 24.9 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Pyridines
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS